全文获取类型
收费全文 | 1847篇 |
免费 | 158篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 24篇 |
妇产科学 | 28篇 |
基础医学 | 219篇 |
口腔科学 | 34篇 |
临床医学 | 199篇 |
内科学 | 564篇 |
皮肤病学 | 8篇 |
神经病学 | 122篇 |
特种医学 | 140篇 |
外科学 | 251篇 |
综合类 | 8篇 |
一般理论 | 2篇 |
预防医学 | 78篇 |
眼科学 | 9篇 |
药学 | 171篇 |
中国医学 | 10篇 |
肿瘤学 | 114篇 |
出版年
2023年 | 25篇 |
2022年 | 13篇 |
2021年 | 36篇 |
2020年 | 41篇 |
2019年 | 49篇 |
2018年 | 55篇 |
2017年 | 46篇 |
2016年 | 48篇 |
2015年 | 61篇 |
2014年 | 75篇 |
2013年 | 78篇 |
2012年 | 126篇 |
2011年 | 121篇 |
2010年 | 82篇 |
2009年 | 54篇 |
2008年 | 103篇 |
2007年 | 122篇 |
2006年 | 101篇 |
2005年 | 95篇 |
2004年 | 97篇 |
2003年 | 81篇 |
2002年 | 92篇 |
2001年 | 29篇 |
2000年 | 31篇 |
1999年 | 24篇 |
1998年 | 19篇 |
1997年 | 16篇 |
1996年 | 10篇 |
1995年 | 12篇 |
1994年 | 10篇 |
1993年 | 10篇 |
1992年 | 9篇 |
1991年 | 11篇 |
1990年 | 12篇 |
1989年 | 14篇 |
1988年 | 15篇 |
1987年 | 23篇 |
1986年 | 14篇 |
1985年 | 10篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1979年 | 16篇 |
1975年 | 9篇 |
1974年 | 12篇 |
1973年 | 9篇 |
1972年 | 8篇 |
1971年 | 11篇 |
1967年 | 10篇 |
1966年 | 7篇 |
1965年 | 6篇 |
排序方式: 共有2012条查询结果,搜索用时 31 毫秒
51.
Pim van der Harst Gerrit van der Steege Rudolf A de Boer Adriaan A Voors Alistair S Hall Marcel J Mulder Wiek H van Gilst Dirk J van Veldhuisen 《Journal of the American College of Cardiology》2007,49(13):1459-1464
OBJECTIVES: This study sought to test the hypothesis that patients with chronic heart failure (CHF) have shorter telomeres compared with age-balanced and gender-balanced healthy individuals. BACKGROUND: Telomere length is considered to be a marker of biological aging. Chronic heart failure might be viewed as a condition associated with accelerated biological aging. METHODS: The telomere length ratio of leukocytes was determined prospectively by a quantitative polymerase chain reaction-based method in a case-control setting involving 803 participants: 183 healthy individuals and 620 CHF patients, ages 40 to 80 years, New York Heart Association functional class II to IV, and left ventricular ejection fraction of 0.40 or less. RESULTS: The median telomere length ratio was 0.64 (interquartile range [IQR] 0.47 to 0.88) in CHF patients compared with 1.05 (IQR 0.86 to 1.29) in control patients (p < 0.001). The telomere length ratio in CHF patients related to severity of disease (median value [IQR] of patients with New York Heart Association class II, III, or IV function was 0.67 [0.48 to 0.92], 0.63 [0.46 to 0.86], and 0.55 [0.46 to 0.75], respectively; p for trend <0.05). In addition, telomeres were shorter in patients with an ischemic compared with a nonischemic etiology of CHF. Patients with none, 1 (coronary, cerebral, or peripheral vascular disease), 2 (any combination of the previous), or 3 atherosclerotic manifestations had a median (IQR) telomere length of 0.72 (0.51 to 1.01), 0.65 (0.48 to 0.87), 0.48 (0.39 to 0.72), and 0.43 (0.27 to 0.67), respectively (p for trend <0.001). CONCLUSIONS: Telomere length is shorter in patients with CHF compared with age-balanced and gender-balanced control patients, and related to the severity of disease. In addition, telomere length was incrementally shorter according to the presence and extent of atherosclerotic disease manifestations. 相似文献
52.
53.
Sex‐specific cardiovascular structure and function in heart failure with preserved ejection fraction
Mauro Gori Carolyn S. P. Lam Deepak K. Gupta Angela B. S. Santos Susan Cheng Amil M. Shah Brian Claggett Michael R. Zile Elisabeth Kraigher‐Krainer Burkert Pieske Adriaan A. Voors Milton Packer Toni Bransford Martin Lefkowitz John J. V. McMurray Scott D. Solomon for the PARAMOUNT Investigators 《European journal of heart failure》2014,16(5):535-542
54.
Burkert Pieske Carsten Tschpe Rudolf A. de Boer Alan G. Fraser Stefan D. Anker Erwan Donal Frank Edelmann Michael Fu Marco Guazzi Carolyn S.P. Lam Patrizio Lancellotti Vojtech Melenovsky Daniel A. Morris Eike Nagel Elisabeth Pieske-Kraigher Piotr Ponikowski Scott D. Solomon Ramachandran S. Vasan Frans H. Rutten Adriaan A. Voors Frank Ruschitzka Walter J. Paulus Petar Seferovic Gerasimos Filippatos 《European journal of heart failure》2020,22(3):391-412
Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the ‘HFA–PEFF diagnostic algorithm’. Step 1 (P=Pre‐test assessment) is typically performed in the ambulatory setting and includes assessment for heart failure symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non‐cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular (LV) ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e′), LV filling pressure estimated using E/e′, left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2–4 points) implies diagnostic uncertainty, in which case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2: Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF. 相似文献
55.
John R. Teerlink Beth A. Davison Gad Cotter Aldo P. Maggioni Naoki Sato Ovidiu Chioncel Georg Ertl G. Michael Felker Gerasimos Filippatos Barry H. Greenberg Peter S. Pang Piotr Ponikowski Christopher Edwards Stefanie Senger Sam L. Teichman Olav Wendelboe Nielsen Adriaan A. Voors Marco Metra 《European journal of heart failure》2020,22(2):315-329
56.
57.
Nils Bomer Niels Grote Beverborg Martijn F. Hoes Koen W. Streng Mathilde Vermeer Martin M. Dokter Jan IJmker Stefan D. Anker John G.F. Cleland Hans L. Hillege Chim C. Lang Leong L. Ng Nilesh J. Samani Jasper Tromp Dirk J. van Veldhuisen Daan J. Touw Adriaan A. Voors Peter van der Meer 《European journal of heart failure》2020,22(8):1415-1423
58.
59.
60.
K. Brundyn M.D. C. F. N. Koegelenberg M.D. Ph.D. A. H. Diacon M.D. Ph.D. M. Louw M.D. P. Schubert M.D. M.I.A.C. C. T. Bolliger M.D. Ph.D. M. M. van den Heuvel M.D. Ph.D. C. A. Wright M.D. Ph.D. F.I.A.C. 《Diagnostic cytopathology》2013,41(4):324-329
There is a paucity of prospective data on flexible bronchoscopy with rapid on‐site evaluation (ROSE) in the setting of superior vena cava (SVC) syndrome. The aims of this prospective study were to assess the diagnostic yield and safety of these investigations and specifically to evaluate the role of ROSE in limiting the need for tissue biopsies. Over a 5‐year period 48 patients (57.4 ± 9.7 years) with SVC syndrome secondary to intrathoracic tumors underwent flexible bronchoscopy with TBNA and ROSE. Endobronchial Forceps biopsy was reserved for visible endobronchial tumors with no on‐site confirmation of diagnostic material. ROSE confirmed diagnostic material in 41 cases (85.4%), and in only one of the remaining cases did the addition of a forceps biopsy increase the diagnostic yield (overall diagnostic yield of 87.5%). No serious complications were noted. The final diagnoses made included nonsmall lung cancer (n = 27), small cell lung cancer (n = 16), and metastatic carcinoma (n = 3). Two undiagnosed cases died of suspected advanced neoplasms (unknown primary tumors). We conclude that TBNA has a high diagnostic yield and is safe in the setting of SVC syndrome. With the addition of ROSE, tissue biopsy is required in the minority of cases. Diagn. Cytopathol. 2013;41:324–329. © 2011 Wiley Periodicals, Inc. 相似文献